HC-1119
- Generic Name
- HC-1119
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Applied Biology, Inc.
- Target Recruit Count
- 602
- Registration Number
- NCT04986176
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 417
- Registration Number
- NCT03851640
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 3
Terminated
- Conditions
- Prostate Cancer MetastaticCastration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Hinova Pharmaceuticals USA, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT03850795
- Locations
- 🇵🇱
NZOZ Centrum Urologiczne Sp zoo, Mysłowice, Slaskie, Poland
🇫🇷Hopital d'Instruction des Armées de Begin, Saint-Mandé, France
🇳🇱Antonius Ziekenhuis, Sneek, Friesland, Netherlands
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Phase 1
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03778047
- Locations
- 🇨🇳
Medical Ethics Committee of Hunan Cancer Hospital, Changsha, China
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03776968
- Locations
- 🇨🇳
Shanghai Changhai Hospital Ethics Committee, Shanghai, China
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Hinova Pharmaceuticals Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03774056
- Locations
- 🇨🇳
Hinova Pharmaceuticals Inc., Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath